Genital herpes: current understanding of diagnosis and treatment

Genital herpes is currently associated with a global prevalence and increasing incidence. Every tenth person of reproductive age is infected with herpes simplex virus type 2. However, the actual prevalence of the virus may be 5–10 times higher, due to the asymptomatic nature of the disease, making it challenging to accurately determine the statistical prevalence. In addition, genital herpes is associated with the risk of developing neurological complications and co-infections. Recent published studies demonstrate an increased risk of human papillomavirus infection and bacterial vaginosis in patients with genital herpes. Women with compromised immune function deserve special attention due to the potential for severe disease. Currently, resistance to acyclic nucleosides and high recurrence rates of genital herpes are observed in a number of clinical cases. The results of the study on the use of combination therapy with dietary supplements containing restriction enzymes (Radaleya) in patients with genital herpes show high clinical efficacy (63.3% of patients had no symptoms as early as the 2nd day of treatment) and a low frequency of repeated episodes (3.3%) during 6–12 months of follow-up.

Conclusion: Taking into account the data from the world literature indicating the existing problem of resistance to first-line drugs for genital herpes and the high risk of recurrence of the disease after treatment, it is advisable to search for new approaches to the choice of therapy. In this regard, the use of the Radaleya dietary supplement, which has a multidirectional antiviral mechanism, in the complex treatment of genital herpes can help to stop the clinical symptoms of the disease, increase the effectiveness of the prescribed treatment, and reduce the likelihood of recurrence of the disease.